Close
Help
Need Help?





JOURNAL

Clinical Medicine Insights: Cardiology

611,609 Journal Article Views | Journal Analytics

Pleiotropic Effects of Antiarrhythmic Agents: Dronedarone in the Treatment of Atrial Fibrillation

Submit a Paper



Publication Date: 11 Aug 2013

Type: Review

Journal: Clinical Medicine Insights: Cardiology

Citation: Clinical Medicine Insights: Cardiology 2013:7 127-140

doi: 10.4137/CMC.S8445

Abstract

Atrial fibrillation remains the most common arrhythmia in clinical practice. Dronedarone is an antiarrhythmic drug for the maintenance of sinus rhythm in patients with atrial fibrillation. Dronedarone is an amiodarone derivative developed to reduce the number of extracardiovascular side effects. Dronedarone has undergone extensive experimental and clinical testing during the last decade. On the aggregate, these studies have highlighted a complex set of pleiotropic actions that may contribute to dronedarone’s antiarrhythmic effects. In this review, we summarize the clinical studies that have evaluated dronedarone and provide an overview of dronedarone's electrophysiological and nonelectrophysiological pleiotropic actions.


Downloads

PDF  (1.68 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML

PMC HTML


Sharing




What Your Colleagues Say About Clinical Medicine Insights: Cardiology
I am impressed by the efficiency at each step of submission in the journal. Based on the first-hand experience, I am confident that this journal will have a great future, and the impact factor will rise rapidly.
Dr Jia Li (Alberta Health Services, Canada)
More Testimonials

Quick Links




Follow Us We make it easy to find new research papers.
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube




SUBJECT HUBS
Author Survey Results
author_survey_results
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.
See Our Results